Otterbein Leo E, Fan Zhigang, Koulmanda Maria, Thronley Thomas, Strom Terry B
aDepartment of Surgery bDepartment of Medicine, Harvard Medical School; Transplant Institute, Beth Israel Deaconess Medical Center; Boston, Massachusetts, USA.
Curr Opin Organ Transplant. 2015 Feb;20(1):8-12. doi: 10.1097/MOT.0000000000000152.
To update knowledge concerning the cause and consequences of the detrimental forms of innate immunity that inevitably occurs in peritransplant period tissue and cellular transplants. In addition, we review the information that a newly discovered, engraftment-promoting, and tolerance-inducing macrophage population is identified and characterized.
The allograft response mounted by adaptive immune cells is shaped by innate immunity. The early allograft response is uniquely intense as a result of activation of the innate immune response created by ischemia reperfusion injury in organ transplants, delayed revascularization of cell transplants, and hypoxia. Inflammation is created by both cellular 'debris' and cytokines. However, a newly discovered prominent, albeit fragile, tissue-resident, noninvasive, and immunoregulatory macrophage promotes engraftment and tolerance. The role of intracellular 'debris' as well as inflammation in evoking detrimental rejection-provoking peritransplant inflammation is emphasized as well as characterization of a prominent and highly immunoregulatory albeit fragile macrophage population that is tissue-resident and does not circulate is characterized.
Opportunity lies in the ability to rein in detrimental peri-transplant inflammation and in the ability to promote the longevity of a subpopulation of highly potent tissue-resident immunoregulatory macrophages.
更新关于移植围手术期组织和细胞移植中不可避免出现的有害形式的固有免疫的原因及后果的知识。此外,我们回顾了一种新发现的、促进植入并诱导耐受的巨噬细胞群体已被识别和表征的相关信息。
适应性免疫细胞引发的同种异体移植反应受固有免疫影响。由于器官移植中的缺血再灌注损伤、细胞移植的血管再通延迟和缺氧所引发的固有免疫反应激活,早期同种异体移植反应格外强烈。炎症由细胞“碎片”和细胞因子共同引发。然而,一种新发现的突出的巨噬细胞,尽管脆弱,但为组织驻留型、非侵袭性且具有免疫调节作用,可促进植入并诱导耐受。强调了细胞内“碎片”以及炎症在引发有害的移植围手术期排斥性炎症中的作用,同时对一种突出的、高度免疫调节但脆弱的、组织驻留且不循环的巨噬细胞群体进行了表征。
机会在于控制有害的移植围手术期炎症的能力,以及促进高效组织驻留免疫调节巨噬细胞亚群寿命的能力。